Approval:
PROTOCOL SYNOPSIS

NUMBER OF SITES 1
RATIONALE
Fecal microbiota therapy (FMT) is an emerging treatment for gastrointestinal disorders marked by an imbalance in the intestinal microbial flora (dysbiosis). It is hypothesized to work by shifting the recipient's microbiota toward a eubiotic microbial community that resists colonization by pathogenic organisms or decreases its inherent inflammatory properties. Several studies now report its efficacy in treatment of severe Clostridium difficile colitis. Preliminary studies using FMT in Ulcerative Colitis (UC) have also met with some success. This is corroborated by several lines of evidence suggesting dysbiosis plays an important role in UC pathogenesis. While a recent study using FMT in patients with irritable bowel syndrome (IBS) and constipation found transplants persist for up to 2 years, the extent to which the microbiota is alterable in UC is not known. Indeed, there may be particular genetic or immunologic factors in UC leading to selection pressure preventing a change in the microbiota. As an initial step into investigating the potential efficacy of stool transplants for Ulcerative Colitis (UC), we propose to determine the feasibility and stability of transplanted microbiota in a series of 10 patients with mild to moderate UC.
STUDY DESIGN
This is a prospective cohort study.
PRIMARY OBJECTIVE
1. Determine the feasibility and durability of fecal microbiota therapy in patients with mild to moderate UC.
SECONDARY OBJECTIVES
1. Determine what donor and recipient factors correlate with engraftment. 2. Determine if there is any endoscopic or clinical improvement in UC disease activity.
NUMBER OF SUBJECTS
10 Recipients and 10 donors. 
RECIPIENT SELECTION CRITERIA
DURATION OF SUBJECT PARTICIPATION AND DURATION OF STUDY
Subjects will be on study for up to 4 months Screening: 2 to 4 weeks Treatment: 1 day Follow-up: 3 months The total duration of the study is expected to be 12 months. 8 months for subject recruitment and 4 months for final subject follow-up.
E CONCOMMITANT MEDICATIONS
Prohibited: Probiotics (2 weeks), Corticosteroids (2 weeks), Biologics (3 months), Immuno-modulators (3 months), Antibiotics (3months) Allowed: Aminosalicylates
EFFICACY EVALUATIONS
Microbiota Engraftment: 16S rRNA sequencing, fluorescence in situ hybridization, and culture of stool and biopsies. Clinical improvement: UCDAI Scores, histology of biopsies, and fecal calprotectin
PRIMARY ENDPOINT • Engraftment of microbiota
SECONDARY ENDPOINTS
• Clinical improvement in UC
SAFETY EVALUATIONS
Patient will be instructed to call the DDC with any change from baseline including worsened abdominal pain, fever, chills, worsened diarrhea. CBC, CMP, ESR, and CRP as well as physical exam and patient history will be performed at 3 months.
STATISTICS Primary Analysis Plan
Both weighted and unweighted UniFrac distances will be calculated in this study. A relative difference of UniFrac distances comparing recipient and donor stool at baseline (inter-individual) and comparing recipient stool prior to transplant at two time points (intra-individual) for each donor recipient pair will be calculated. This value multiplied by 50% will be the threshold value (TV) to determine if the transplant engrafts and is stable. UniFrac distances comparing the recipient preand post-transplant will need to be >(intra-individual variation of the recipient+TV). In addition, UniFrac distances comparing the recipient post-transplant with the donor will need to be <(intraindividual variation of the donor+TV). Engraftment will be defined as meeting both of these criteria at 7 days. Stability will be defined as meeting both these criteria at 1 month or 3 months.
Rationale for Number of Subjects
This study with 10 pairs is powered to detect whether transplantation engrafts. If we see any trend toward clinical benefit this will be rational for pursuing additional studies that are powered for this purpose.
BACKGROUND
FMT is an emerging therapy that has been gaining considerable recent attention (Khoruts A 2011). It has been shown through several trials to be an effective treatment for refractory Clostridium difficile colitis (Surawicz 2011). Analysis of the microbiota in a patient with C. difficile post FMT demonstrated a change in the microbiota that was more reflective of the donor than the recipient (Khoruts et al 2010) . In a series of 10 patients undergoing FMT with a spectrum of GI diseases including IBS, constipation, and Crohn's disease, the post transplant microbiota was found to be more similar to the donor stool as long as 2 years after transplant. (Grehan MJ 2010) There are reports of FMT being used successfully to treat refractory ulcerative colitis. (Borody et al 2003) . Dr. Borody reports on 6 patients in whom FMT was curative of severe refractory ulcerative colitis for up to 13 years off conventional treatment. Based on personal communication, these six patients were subset of 40 patients. Interestingly, in many of the remaining patients, serial transplantation was required to achieve clinical remission. While transplants in other GI disorders have persisted for up to two years, the extent to which the microbiota in UC is alterable and durable is not known. Indeed, the patient's microbiota may, in part, be under genetically or immunologically determined selection pressure of the patient's immune system and may resist change. In this study, we aim to determine the engraftment durability in 10 patients as an initial step to investigating FMT's therapeutic potential for UC.
STUDY RATIONALE
Risk / Benefit Assessment
FMT for other indications including C.difficile is well tolerated. There are no adverse events reported in the literature to date. The risks associated with this study include the following:
1. Risk of contracting an infectious agent from the stool transplant. We will be screening the donor with American Association of Blood Banks Questionnaire and with the below mentioned stool and serology tests to limit the possibility of transmission of infection. 2. Risk of bleeding, perforation, infection, side effects from sedating medications from the colonoscopy and sigmoidoscopy with biopsy. The colonoscopy is standard of care. The flexible sigmoidoscopy with biopsy is part of the study protocol and does increase risk of bleeding perforation, and infection. This procedure will be performed unsedated so the added risk of sedation does not pertain. 3. Risk of progressive disease. Patients who are already on 5-ASA will be maintained on 5-ASA. There may be some patients in whom we discontinue biologics or immunosuppressive medications prior to enrollment and there is the risk of worsened disease. There is also the risk of worsened disease in not progressing with standard escalation therapy during the duration of the study.
STUDY OBJECTIVES
Primary Objective
1. The primary objective is to determine the feasibility and durability of fecal microbiota therapy in patients with mild to moderate UC.
Secondary Objectives
Determine if there is any clinical improvement in UC as measured by endoscopic
appearance, histology, UCDAI scores, and fecal calprotectin levels.
2. Determine what donor and recipient factors correlate with engraftment.
STUDY DESIGN
Study Overview
This is a single center, prospective cohort study. 10 recipient/donor pairs are planned. Each recipient will undergo a single session of FMT. Biopsies will be collected immediately prior to FMT and 1 month afterward. Stool will be collected at 2 time points (1 week apart) before FMT and 3 time points after FMT (1week, 1 month, 3 months). Donor stool will be collected at two time points before FMT.
Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study.
The following treatment regimen will be used:
• 300cc of stool mixture (3ml:1grams of normal saline: donor stool)
Total duration of subject participation will be 4 months. Total duration of the study is expected to be 1 year.
CRITERIA FOR EVALUATION
Primary Endpoint
• Engraftment of donor microbiota as measured by UniFrac distances from baseline to 1 month.
Secondary Endpoints
• Engraftment of donor microbiota as measured by UniFrac distances from baseline to 3 months.
• Clinical improvement in UC disease activity as measured by UCDAI.
• Decrease in fecal calprotectin level
Safety Evaluations
• Patients will be assessed at a 3 month evaluation with a physical exam and labs including CBC, CMP, ESR, and CRP. We do not expect adverse events given there are no adverse events reported in the literature of FMT.
SUBJECT SELECTION
Study Population
Subjects with a diagnosis of ulcerative colitis who meet the inclusion and exclusion criteria will be eligible for participation in this study. Donors will be a significant other, family member or friend of the recipient and will also need to meet exclusion and inclusion criteria.
Recipient Inclusion Criteria
1. Male or female ≥ 18 years of age at Visit 1.
2. Prior documentation of a UC diagnosis as evidenced by endoscopic and histologic evaluation.
Medications and Treatments
Standard therapy for UC is allowed except for treatments noted in the exclusion criteria described above and as noted in the prohibited medications section below.
The following medications are prohibited during the study and administration will be considered a protocol violation.
• Steroids (2 week washout)
• Probiotics (2 week washout)
• Immunomodulators (3 month washout)
• Biologics (3 month washout)
• Antibiotics (3 month washout)
The following medications are allowed during the study.
• Aminosalicylates
STUDY TREATMENTS
Study will involve administration of 300cc of a stool saline mixture. The stool saline mixture will be prepared by adding 3ml of sterile normal saline to 1mg of donor stool. The full 300cc of stool saline mixture will be strained through two 4x4 gauze sheets to remove particulate matter that could clog the colonoscope. Five 60cc syringes will be loaded with the mixture and administered to the terminal ileum and right colon. After colonoscopy that patient will be administered loperamide 4mg PO times one and will lye recumbent for 3 hours.
STUDY PROCEDURES AND GUIDELINES
A Schedule of Events representing the required testing procedures to be performed for the duration of the study is diagrammed in Appendix 1 and Appendix 2.
Prior to conducting any study-related activities, written informed consent and the Health Insurance Portability and Accountability Act (HIPAA) authorization must be signed and dated by the donor and recipient.
Clinical Assessments
Concomitant Medications
All concomitant medication and concurrent therapies will be documented at baseline and at the 3 month visit. Dose, route, unit frequency of administration, and indication for administration and dates of medication will be captured.
ADVERSE EXPERIENCE REPORTING AND DOCUMENTATION
Dr. Tim Zisman should be contacted directly at this number to report medical concerns or questions regarding safety.
Phone: (206) 598-4377
DISCONTINUATION AND REPLACEMENT OF SUBJECTS
Withdrawal of Subjects from the Study
A subject may be withdrawn from the study at any time if the subject, the investigator, or the Sponsor feels that it is not in the subject's best interest to continue.
All subjects are free to withdraw from participation at any time, for any reason, specified or unspecified, and without prejudice.
Reasonable attempts will be made by the investigator to provide a reason for subject withdrawals. The reason for the subject's withdrawal from the study will be specified in the subject's source documents.
Replacement of Subjects
Subjects who withdraw from the study will be replaced.
PROTOCOL VIOLATIONS
A protocol violation occurs when the subject fails to adhere to significant protocol requirements affecting the inclusion, exclusion, subject safety and primary endpoint criteria. Protocol violations for this study include, but are not limited to, the following:
• Failure to meet inclusion/exclusion criteria
• Use of a prohibited concomitant medication
ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS
The study will be conducted according to the Declaration of Helsinki, Protection of Human Volunteers (21 CFR 50), Institutional Review Boards (21 CFR 56), and Obligations of Clinical Investigators (21 CFR 312).
To maintain confidentiality, all laboratory specimens, evaluation forms, reports and other records will be identified by a coded number and initials only. All study records will be kept in a locked file cabinet and code sheets linking a patient's name to a patient identification number will be stored separately. Clinical information will not be released without written permission of the subject, except as necessary for monitoring by the FDA. The Investigator must also comply with all applicable privacy regulations (e.g., Health Insurance Portability and Accountability Act of 1996).
Protocol Amendments
Protocol amendments cannot be implemented without prior written IRB/IEC approval except as necessary to eliminate immediate safety hazards to patients. A protocol amendment intended to eliminate an apparent immediate hazard to patients may be implemented immediately, provided the IRBs are notified within five working days.
Institutional Review Boards and Independent Ethics Committees
The protocol and consent form will be reviewed and approved by the IRB/IEC of each participating center prior to study initiation. Serious adverse experiences regardless of causality will be reported to the IRB/IEC in accordance with the standard operating procedures and policies of the IRB/IEC, and the Investigator will keep the IRB/IEC informed as to the progress of the study. The Investigator will obtain assurance of IRB/IEC compliance with regulations.
Protocol and/or informed consent modifications or changes may not be initiated without prior written IRB/IEC approval except when necessary to eliminate immediate hazards to the patients or when the change(s) involves only logistical or administrative aspects of the study. Such modifications will be submitted to the IRB/IEC and written verification that the modification was submitted and subsequently approved should be obtained.
The IRB/IEC must be informed of revisions to other documents originally submitted for review; serious and/or unexpected adverse experiences occurring during the study in accordance with the standard operating procedures and policies of the IRB; new information that may affect adversely the safety of the patients of the conduct of the study; an annual update and/or request for re-approval; and when the study has been completed.
Informed Consent Form
Informed The Investigator will prepare the informed consent form and HIPAA authorization and provide the documents to the Sponsor or designee for approval prior to submission to the IRB/IEC. The consent form generated by the Investigator must be acceptable to the Sponsor and be approved by the IRB/IEC. The written consent document will embody the elements of informed consent as described in the International Conference on Harmonisation and will also comply with local regulations. The Investigator will send an IRB/IEC-approved copy of the Informed Consent Form to the Sponsor (or designee) for the study file.
A properly executed, written, informed consent will be obtained from each subject prior to entering the subject into the trial. Information should be given in both oral and written form and subjects must be given ample opportunity to inquire about details of the study. If appropriate and required by the local IRB/IEC, assent from the subject will also be obtainedA copy of the signed consent form will be given to the subject and the original will be maintained with the subject's study records. 
APPENDIX 1. STUDY FLOW SHEET
